| Year |
Citation |
Score |
| 2025 |
Li H, Chatla S, Liu X, Tian Z, Vekariya U, Wang P, Kim D, Octaviani S, Lian Z, Morton G, Feng Z, Yang D, Sullivan-Reed K, Childers W, Yu X, ... ... Skorski T, et al. ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Letters. 217505. PMID 39892701 DOI: 10.1016/j.canlet.2025.217505 |
0.328 |
|
| 2024 |
Le BV, Vekariya U, Toma MM, Nieborowska-Skorska M, Caron MC, Gozdecka M, Haydar Z, Walsh M, Ghosh J, Vaughan-Williams E, Podszywalow-Bartnicka P, Kukuyan AM, Ziolkowska S, Hadzijusufovic E, Chandramouly G, ... ... Skorski T, et al. DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells. Biorxiv : the Preprint Server For Biology. PMID 39411165 DOI: 10.1101/2024.09.15.613155 |
0.499 |
|
| 2024 |
Barszczewska-Pietraszek G, Czarny P, Drzewiecka M, Błaszczyk M, Radek M, Synowiec E, Wigner-Jeziorska P, Sitarek P, Szemraj J, Skorski T, Śliwiński T. Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells. International Journal of Molecular Sciences. 25. PMID 39273083 DOI: 10.3390/ijms25179134 |
0.47 |
|
| 2024 |
Ito F, Li Z, Minakhin L, Chandramouly G, Tyagi M, Betsch R, Krais JJ, Taberi B, Vekariya U, Calbert M, Skorski T, Johnson N, Chen XS, Pomerantz RT. Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM. Nature Communications. 15: 7003. PMID 39143110 DOI: 10.1038/s41467-024-51351-4 |
0.325 |
|
| 2024 |
Vekariya U, Minakhin L, Chandramouly G, Tyagi M, Kent T, Sullivan-Reed K, Atkins J, Ralph D, Nieborowska-Skorska M, Kukuyan AM, Tang HY, Pomerantz RT, Skorski T. PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks. Nature Communications. 15: 5822. PMID 38987289 DOI: 10.1038/s41467-024-50158-7 |
0.32 |
|
| 2024 |
Fried W, Tyagi M, Minakhin L, Chandramouly G, Tredinnick T, Ramanjulu M, Auerbacher W, Calbert M, Rusanov T, Hoang T, Borisonnik N, Betsch R, Krais JJ, Wang Y, Vekariya UM, ... ... Skorski T, et al. Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors. Nature Communications. 15: 2862. PMID 38580648 DOI: 10.1038/s41467-024-46593-1 |
0.356 |
|
| 2023 |
Calbert ML, Chandramouly G, Adams CM, Saez-Ayala M, Kent T, Tyagi M, Ayyadevara VSSA, Wang Y, Krais JJ, Gordon J, Atkins J, Toma MM, Betzi S, Boghossian AS, Rees MG, ... ... Skorski T, et al. 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular Cancer Therapeutics. PMID 38064712 DOI: 10.1158/1535-7163.MCT-23-0487 |
0.355 |
|
| 2023 |
Liu ZS, Sinha S, Bannister M, Song A, Arriaga-Gomez E, McKeeken AJ, Bonner EA, Hanson BK, Sarchi M, Takashima K, Zong D, Corral VM, Nguyen E, Yoo J, Chiraphapphaiboon W, ... ... Skorski T, et al. R-loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 inhibition by triggering transcription-replication conflicts. Cancer Research. PMID 37967363 DOI: 10.1158/0008-5472.CAN-23-3239 |
0.319 |
|
| 2023 |
Drzewiecka M, Jaśniak D, Barszczewska-Pietraszek G, Czarny P, Kobrzycka A, Wieczorek M, Radek M, Szemraj J, Skorski T, Śliwiński T. Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. Journal of Personalized Medicine. 13. PMID 37763083 DOI: 10.3390/jpm13091315 |
0.328 |
|
| 2023 |
Drzewiecka M, Gajos-Michniewicz A, Hoser G, Jaśniak D, Barszczewska-Pietraszek G, Sitarek P, Czarny P, Piekarski J, Radek M, Czyż M, Skorski T, Śliwiński T. Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. Genes. 14. PMID 37372475 DOI: 10.3390/genes14061295 |
0.326 |
|
| 2023 |
Sullivan-Reed K, Toma MM, Drzewiecka M, Nieborowska-Skorska M, Nejati R, Karami A, Wasik MA, Sliwinski T, Skorski T. Simultaneous targeting of DNA polymerase theta and PARP1 or RAD52 triggers dual synthetic lethality in homologous recombination-deficient leukemia cells. Molecular Cancer Research : McR. PMID 37358557 DOI: 10.1158/1541-7786.MCR-22-1035 |
0.507 |
|
| 2023 |
Wolczyk M, Serwa R, Kominek A, Klejman A, Milek J, Chwałek M, Turos-Korgul L, Charzyńska A, Dabrowski M, Dziembowska M, Skorski T, Piwocka K, Podszywalow-Bartnicka P. TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment. Iscience. 26: 106543. PMID 37123244 DOI: 10.1016/j.isci.2023.106543 |
0.315 |
|
| 2023 |
Li H, Chatla S, Liu X, Vekariya U, Kim D, Walt M, Lian Z, Morton G, Feng Z, Yang D, Liu H, Reed K, Childers W, Yu X, Madzo J, ... ... Skorski T, et al. Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells. Research Square. PMID 37066268 DOI: 10.21203/rs.3.rs-2688694/v1 |
0.398 |
|
| 2023 |
Golovine K, Abalakov G, Lian Z, Chatla S, Karami A, Chitrala KN, Madzo J, Nieborowska-Skorska M, Huang J, Skorski T. ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. Blood Cancer Journal. 13: 42. PMID 36959186 DOI: 10.1038/s41408-023-00810-0 |
0.551 |
|
| 2022 |
Barszczewska-Pietraszek G, Drzewiecka M, Czarny P, Skorski T, Śliwiński T. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours. International Journal of Molecular Sciences. 24. PMID 36613762 DOI: 10.3390/ijms24010319 |
0.332 |
|
| 2022 |
Vekariya U, Toma MM, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, ... ... Skorski T, et al. DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage. Blood. PMID 36580665 DOI: 10.1182/blood.2022018428 |
0.516 |
|
| 2022 |
Drzewiecka M, Barszczewska-Pietraszek G, Czarny P, Skorski T, Śliwiński T. Synthetic Lethality Targeting Polθ. Genes. 13. PMID 35741863 DOI: 10.3390/genes13061101 |
0.409 |
|
| 2021 |
Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuwille WMB, Nacson J, Hulse M, Keith K, Madzo J, Caruso LB, Gazze Z, Lian Z, Padella A, Chitrala KN, ... ... Skorski T, et al. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer Research. PMID 34215619 DOI: 10.1158/0008-5472.CAN-20-3761 |
0.446 |
|
| 2021 |
Głowacki S, Synowiec E, Szwed M, Toma M, Skorski T, Śliwiński T. Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells. Biomolecules. 11. PMID 33924068 DOI: 10.3390/biom11040610 |
0.433 |
|
| 2021 |
Chandramouly G, Liao S, Rusanov T, Borisonnik N, Calbert ML, Kent T, Sullivan-Reed K, Vekariya U, Kashkina E, Skorski T, Yan H, Pomerantz RT. Polθ promotes the repair of 5'-DNA-protein crosslinks by microhomology-mediated end-joining. Cell Reports. 34: 108820. PMID 33691100 DOI: 10.1016/j.celrep.2021.108820 |
0.376 |
|
| 2020 |
Hewlett E, Toma M, Sullivan-Reed K, Gordo J, Sliwinski T, Tulin A, Childers WE, Skorski T. Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia. Medicinal Chemistry Research : An International Journal For Rapid Communications On Design and Mechanisms of Action of Biologically Active Agents. 29: 962-978. PMID 33071527 DOI: 10.1007/S00044-020-02537-0 |
0.381 |
|
| 2020 |
Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, Yao JC, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, ... ... Skorski T, et al. TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell Reports. 33: 108221. PMID 33027668 DOI: 10.1016/j.celrep.2020.108221 |
0.394 |
|
| 2019 |
Nieborowska-Skorska M, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Skorski T. Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor. Blood Advances. 3: 4050-4054. PMID 31816060 DOI: 10.1182/Bloodadvances.2019000756 |
0.51 |
|
| 2019 |
Kirschner M, Bornemann A, Schubert C, Gezer D, Kricheldorf K, Isfort S, Brümmendorf TH, Schemionek M, Chatain N, Skorski T, Koschmieder S. Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms. Annals of Hematology. PMID 31748924 DOI: 10.1007/S00277-019-03836-2 |
0.459 |
|
| 2019 |
Toma M, Sullivan-Reed K, Śliwiński T, Skorski T. RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies. Cancers. 11. PMID 31615159 DOI: 10.3390/Cancers11101561 |
0.503 |
|
| 2019 |
Flis S, Bratek E, Chojnacki T, Piskorek M, Skorski T. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells. Cancers. 11. PMID 31614827 DOI: 10.1182/Blood-2019-129093 |
0.517 |
|
| 2019 |
Black SJ, Ozdemir AY, Kashkina E, Kent T, Rusanov T, Ristic D, Shin Y, Suma A, Hoang T, Chandramouly G, Siddique LA, Borisonnik N, Sullivan-Reed K, Mallon JS, Skorski T, et al. Molecular basis of microhomology-mediated end-joining by purified full-length Polθ. Nature Communications. 10: 4423. PMID 31562312 DOI: 10.1038/S41467-019-12272-9 |
0.41 |
|
| 2019 |
Karpova Y, Wu C, Divan A, McDonnell ME, Hewlett E, Makhov P, Gordon J, Ye M, Reitz A, Childers WE, Skorski T, Kolenko V, Tulin AV. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochemical Pharmacology. PMID 30880062 DOI: 10.1016/J.Bcp.2019.03.021 |
0.387 |
|
| 2019 |
Machnicki MM, Pepek M, Solarska I, Niesiobedzka-Krezel J, Seferynska I, Gora Tybor J, Zawada M, Sacha T, Sawicki W, Wasilewska E, Pruszczyk K, Rydzanicz M, Ploski R, Skorski T, Stoklosa T. ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia Blood. 134: 4148-4148. DOI: 10.1182/Blood-2019-129834 |
0.367 |
|
| 2019 |
Chroscicki P, Tybuchowska A, Swatler J, Samsel R, Cichocki A, Podszywalow-Bartnicka P, Roszkowska-Purska K, Tenderenda M, Smiertka W, Nieborowska-Skorska M, Skorski T, Piwocka K. Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in pancreatic cancers Annals of Oncology. 30: vii18. DOI: 10.1093/Annonc/Mdz413.063 |
0.502 |
|
| 2018 |
Piwocka K, Podszywałow-Bartnicka P, Skorski T. BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters. Postepy Biochemii. 64: 141-147. PMID 30656896 DOI: 10.18388/Pb.2018_124 |
0.441 |
|
| 2018 |
Toma M, Witusik-Perkowska M, Szwed M, Stawski R, Szemraj J, Drzewiecka M, Nieborowska-Skorska M, Radek M, Kolasa P, Matlawska-Wasowska K, Sliwinski T, Skorski T. Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent. Oncotarget. 9: 36867-36877. PMID 30627327 DOI: 10.18632/Oncotarget.26409 |
0.542 |
|
| 2018 |
Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T. Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leukemia & Lymphoma. 1-4. PMID 30277116 DOI: 10.1080/10428194.2018.1520988 |
0.384 |
|
| 2018 |
Podszywalow-Bartnicka P, Maifrede S, Le BV, Nieborowska-Skorska M, Piwocka K, Skorski T. PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions. Leukemia & Lymphoma. 1-3. PMID 29932782 DOI: 10.1182/Blood-2018-99-115041 |
0.543 |
|
| 2018 |
Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, ... ... Skorski T, et al. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Reports. 23: 3127-3136. PMID 29898385 DOI: 10.1016/J.Celrep.2018.05.034 |
0.808 |
|
| 2018 |
Maifrede S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, ... ... Skorski T, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. PMID 29784639 DOI: 10.1182/Blood-2018-02-834895 |
0.854 |
|
| 2018 |
Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I. Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget. 9: 10585-10605. PMID 29535829 DOI: 10.18632/Oncotarget.24291 |
0.46 |
|
| 2018 |
Toma M, Skorski T, Sliwinski T. DNA double strand break repair - related synthetic lethality. Current Medicinal Chemistry. PMID 29421999 DOI: 10.2174/0929867325666180201114306 |
0.486 |
|
| 2017 |
Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T. MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Advances. 1: 1467-1472. PMID 29296788 DOI: 10.1182/Bloodadvances.2017006247 |
0.336 |
|
| 2017 |
Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Froehling S, Balachandran S, Skorski T, et al. PKC epsilon is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29127121 DOI: 10.1158/1078-0432.Ccr-17-2684 |
0.408 |
|
| 2017 |
Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, Skorski T. Drugging DNA repair to target T-ALL cells. Leukemia & Lymphoma. 1-4. PMID 29115896 DOI: 10.1080/10428194.2017.1397662 |
0.787 |
|
| 2017 |
Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, ... ... Skorski T, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. PMID 29042365 DOI: 10.1182/Blood-2017-05-784942 |
0.84 |
|
| 2017 |
Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan K, Langer SK, Nejadi R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, ... Skorski T, et al. IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors. Molecular Cancer Research : McR. PMID 28634224 DOI: 10.1158/1541-7786.Mcr-16-0468 |
0.832 |
|
| 2017 |
Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, ... ... Skorski T, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. The Journal of Clinical Investigation. PMID 28481221 DOI: 10.1172/Jci90825 |
0.844 |
|
| 2017 |
Mukherjee K, Sha X, Magimaidas A, Maifrede S, Skorski T, Bhatia R, Hoffman B, Liebermann DA. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia. Oncotarget. PMID 28086219 DOI: 10.18632/Oncotarget.14580 |
0.455 |
|
| 2016 |
Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Skorski T, Białas AJ, Sakowicz T, Kowalczyk T, Radek M, Wysokińska H, Śliwiński T. Transformed Root Extract of Leonurus sibiricus Induces Apoptosis through Intrinsic and Extrinsic Pathways in Various Grades of Human Glioma Cells. Pathology Oncology Research : Por. PMID 28032310 DOI: 10.1007/S12253-016-0170-6 |
0.348 |
|
| 2016 |
Zhou C, Martinez E, Di Marcantonio D, Patel-Solanki N, Aghayev T, Peri S, Ferraro F, Skorski T, Scholl C, Fröhling S, Balachandran S, Wiest DL, Sykes SM. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. PMID 27840425 DOI: 10.1038/Leu.2016.329 |
0.404 |
|
| 2016 |
Podszywalow-Bartnicka P, Cmoch A, Wolczyk M, Bugajski L, Tkaczyk M, Dadlez M, Nieborowska-Skorska M, Koromilas AE, Skorski T, Piwocka K. Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes. Oncotarget. PMID 27802179 DOI: 10.18632/Oncotarget.12941 |
0.478 |
|
| 2016 |
Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. PMID 27705909 DOI: 10.18632/Oncotarget.12270 |
0.522 |
|
| 2016 |
Skała E, Sitarek P, Toma M, Szemraj J, Radek M, Nieborowska-Skorska M, Skorski T, Wysokińska H, Śliwiński T. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots. The Journal of Pharmacy and Pharmacology. PMID 27696406 DOI: 10.1111/Jphp.12619 |
0.358 |
|
| 2016 |
Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Research. PMID 26873923 DOI: 10.1093/Nar/Gkw087 |
0.475 |
|
| 2016 |
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, ... ... Skorski T, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. PMID 26864341 DOI: 10.1182/Blood-2015-11-681171 |
0.84 |
|
| 2016 |
Sullivan K, Cramer-Morales K, McElroy DL, Ostrov DA, Haas K, Childers W, Hromas R, Skorski T. Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection. Plos One. 11: e0147230. PMID 26784987 DOI: 10.1371/Journal.Pone.0147230 |
0.394 |
|
| 2016 |
Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T. Mitochondrial mutagenesis in BCR-ABL1-expressing cells sensitive and resistant to imatinib. Acta Biochimica Polonica. PMID 26757169 DOI: 10.18388/Abp.2015_1189 |
0.549 |
|
| 2016 |
Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Nieborowska-Skorska M, Kolasa M, Skorski T, Wysokińska H, Śliwiński T. A preliminary study of apoptosis induction in glioma cells via alteration of the Bax/Bcl-2-p53 axis by transformed and non-transformed root extracts of Leonurus sibiricus L. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. PMID 26743778 DOI: 10.1007/S13277-015-4714-2 |
0.381 |
|
| 2016 |
Maifrede S, Martin K, Podszywalow-Bartnicka P, Katherine S, Langer S, Nejati R, Dasgupta Y, Gritsyuk D, Nieborowska-Skorska M, Lupey L, Piwocka K, Wasik MA, Tempera I, Skorski T. IGH/MYC Translocation in Burkitt Lymphoma Is Associated with BRCA2 Deficiency and Synthetic Lethality By PARP1 Inhibitors Blood. 128: 4111-4111. DOI: 10.1182/Blood.V128.22.4111.4111 |
0.829 |
|
| 2015 |
Synowiec E, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T, Blasiak J. Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib. Biomed Research International. 2015: 673512. PMID 26618175 DOI: 10.1155/2015/673512 |
0.461 |
|
| 2015 |
Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT. Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers. Chemistry & Biology. 22: 1491-504. PMID 26548611 DOI: 10.1016/J.Chembiol.2015.10.003 |
0.43 |
|
| 2015 |
Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T. Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib. Bioresearch Open Access. 4: 334-42. PMID 26309809 DOI: 10.1089/Biores.2015.0022 |
0.502 |
|
| 2015 |
Synowiec E, Hoser G, Wojcik K, Pawlowska E, Skorski T, Błasiak J. UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib. International Journal of Molecular Sciences. 16: 18111-28. PMID 26251899 DOI: 10.3390/Ijms160818111 |
0.542 |
|
| 2015 |
Sullivan K, Bolton-Gillespie E, Nieborowska-Skorska M, Cerny-Reiterer S, Valent P, Muschen M, Pomerantz R, Mazin A, Skorski T. Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors Blood. 126: 50-50. DOI: 10.1182/Blood.V126.23.50.50 |
0.621 |
|
| 2015 |
Sullivan K, Cramer-Morales K, McElroy DL, Ostrov D, Haas K, Nieborowska-Skorska M, Childers W, Mazin A, Hromas RA, Pomerantz R, Skorski T. Identification of a Small Molecule Inhibitor of RAD52 to Induce Synthetic Lethality in BRCA-Deficient Leukemias Blood. 126: 4434-4434. DOI: 10.1182/Blood.V126.23.4434.4434 |
0.565 |
|
| 2014 |
Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. Cell Cycle (Georgetown, Tex.). 13: 3727-41. PMID 25483082 DOI: 10.4161/15384101.2014.965013 |
0.803 |
|
| 2014 |
Toma M, Skorski T, Sliwiński T. [Synthetic lethality as a functional tool in basic research and in anticancer therapy]. PostȩPy Higieny I Medycyny DośWiadczalnej (Online). 68: 1091-103. PMID 25228518 DOI: 10.5604/17322693.1119792 |
0.358 |
|
| 2014 |
Nieborowska-Skorska M, Flis S, Skorski T. AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells. Leukemia. 28: 2416-8. PMID 25151958 DOI: 10.1038/Leu.2014.249 |
0.427 |
|
| 2014 |
Nieborowska-Skorska M, Sullivan K, Podszywalow-Bartnicka P, Hoser G, Bolton-Gillespie E, Cramer-Morales K, Slupianek A, Zhou C, Cerny-Reiterer S, Stoklosa T, Sykes SM, Valent P, Civin CI, Muschen M, Minden MD, ... ... Skorski T, et al. Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells Blood. 124: 480-480. DOI: 10.1182/Blood.V124.21.480.480 |
0.587 |
|
| 2014 |
Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K. Downregulation of BRCA1 Protein in BCR-ABL1–positive Cells Depends on Tiar-Mediated Repression of BRCA1 mRNA Translation Blood. 124: 3129-3129. DOI: 10.1182/Blood.V124.21.3129.3129 |
0.804 |
|
| 2014 |
Nieborowska-Skorska M, Flis S, Skorski T. Chronic Myeloid Leukemia Stem Cells (LSCs) and Leukemia Progenitor Cells (LPCs) Display Overlapping and Unique Mechanisms of Genomic Instability: The Role of PI3k-AKT and PI3k-Rac2-PAK Pathways Blood. 124: 1791-1791. DOI: 10.1182/Blood.V124.21.1791.1791 |
0.639 |
|
| 2013 |
Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, ... ... Skorski T, et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 122: 1293-304. PMID 23836560 DOI: 10.1182/Blood-2013-05-501072 |
0.541 |
|
| 2013 |
Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia. 27: 2253-4. PMID 23604228 DOI: 10.1038/Leu.2013.123 |
0.387 |
|
| 2013 |
Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, ... ... Skorski T, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 121: 4175-83. PMID 23543457 DOI: 10.1182/Blood-2012-11-466938 |
0.605 |
|
| 2013 |
Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leukemia & Lymphoma. 54: 1151-8. PMID 23121619 DOI: 10.3109/10428194.2012.745524 |
0.397 |
|
| 2013 |
Mukherjee K, Sha X, Skorski T, Bhatia R, Hoffman B, Liebermann D. GADD45a Is a Tumor Suppressor in BCR-ABL-Driven Leukemogenesis Blood. 122: 1467-1467. DOI: 10.1182/Blood.V124.21.4530.4530 |
0.539 |
|
| 2013 |
Nieborowska-Skorska M, Slupianek A, Hoser G, Bolton-Gillespie E, Tulin A, Cerny-Reiterer S, Valent P, Muschen M, Sykes SM, Skorski T. Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells Blood. 122: 810-810. DOI: 10.1182/Blood.V122.21.810.810 |
0.646 |
|
| 2013 |
Dasgupta Y, Koptyra M, Nieborowska-Skorska M, Gillespie EB, Stoklosa T, Hoser G, Wasik M, Muschen M, Richardson C, Skorski T. Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive Leukemias Blood. 122: 1466-1466. DOI: 10.1182/Blood.V122.21.1466.1466 |
0.661 |
|
| 2012 |
Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. Leukemia. 27: 629-34. PMID 23047475 DOI: 10.1038/Leu.2012.294 |
0.613 |
|
| 2012 |
Flis K, Irvine D, Copland M, Bhatia R, Skorski T. Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leukemia & Lymphoma. 53: 2474-8. PMID 22616753 DOI: 10.3109/10428194.2012.696313 |
0.466 |
|
| 2012 |
Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, ... ... Skorski T, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 119: 4253-63. PMID 22411871 DOI: 10.1182/Blood-2011-10-385658 |
0.831 |
|
| 2012 |
Skorski T. Genetic mechanisms of chronic myeloid leukemia blastic transformation. Current Hematologic Malignancy Reports. 7: 87-93. PMID 22328017 DOI: 10.1007/S11899-012-0114-5 |
0.484 |
|
| 2012 |
Falinski R, Nieborowska-Skorska M, Skorski T. BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks. Leukemia Research. 36: 241-4. PMID 22036635 DOI: 10.1016/J.Leukres.2011.10.007 |
0.492 |
|
| 2012 |
Bolton E, Schemionek M, Klein H, Hoser G, Flis S, Lange T, Kerstiens L, Nieborowska-Skorska M, Müller MC, Modi H, Bhatia R, Koschmieder S, Skorski T. Genomic Instability in CML-CP originates From the Most Primitive Imatinib-Refractory Leukemia Stem Cells Blood. 120: 909-909. DOI: 10.1182/Blood.V120.21.909.909 |
0.845 |
|
| 2012 |
Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Synowiec E, Blasiak J, Bellacosa A, Skorski T. BCR-ABL1 Kinase Inhibits DNA Glycosylases to Enhance Oxidative DNA Damage and Stimulate Genomic Instability Blood. 120: 520-520. DOI: 10.1182/Blood.V120.21.520.520 |
0.613 |
|
| 2012 |
Cramer K, Nieborowska-Skorska M, Slupianek A, Sliwinski T, Irvine D, Copland M, Skorski T. RAD52-Dependent Synthetic Lethality Eradicates Leukemia Stem Cells Blood. 120: 3-3. DOI: 10.1182/Blood.V120.21.3.3 |
0.652 |
|
| 2011 |
Skorski T. BCR-ABL1 kinase: hunting an elusive target with new weapons. Chemistry & Biology. 18: 1352-3. PMID 22118668 DOI: 10.1016/J.Chembiol.2011.11.001 |
0.463 |
|
| 2011 |
Mughal TI, Radich JP, Van Etten RA, Quintás-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. American Journal of Hematology. 86: 811-9. PMID 21850662 DOI: 10.1002/Ajh.22097 |
0.385 |
|
| 2011 |
Virgili A, Koptyra M, Dasgupta Y, Glodkowska-Mrowka E, Stoklosa T, Nacheva EP, Skorski T. Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele. Cancer Research. 71: 5381-6. PMID 21693657 DOI: 10.1158/0008-5472.Can-11-0068 |
0.843 |
|
| 2011 |
Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 118: 1062-8. PMID 21653319 DOI: 10.1182/Blood-2010-09-307256 |
0.851 |
|
| 2011 |
Koptyra M, Stoklosa T, Hoser G, Glodkowska-Mrowka E, Seferynska I, Klejman A, Blasiak J, Skorski T. Monoubiquitinated Fanconi anemia D2 (FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis. Leukemia. 25: 1259-67. PMID 21519342 DOI: 10.1038/Leu.2011.91 |
0.629 |
|
| 2011 |
Skorski T. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leukemia & Lymphoma. 52: 23-9. PMID 21299457 DOI: 10.3109/10428194.2010.546912 |
0.546 |
|
| 2011 |
Slupianek A, Poplawski T, Jozwiakowski SK, Cramer K, Pytel D, Stoczynska E, Nowicki MO, Blasiak J, Skorski T. BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Research. 71: 842-51. PMID 21123451 DOI: 10.1158/0008-5472.Can-10-1066 |
0.608 |
|
| 2011 |
Cramer K, Bolton E, Nieborowska-Skorska M, Flis S, Skorski T. Targeting DNA Repair Gene, RAD52, Induces Exhaustion of the Proliferating CML-CP Leukemia Stem Cells Carrying Oxidative DNA Damage Blood. 118: 447-447. DOI: 10.1182/Blood.V118.21.447.447 |
0.85 |
|
| 2011 |
Bolton E, Schemionek M, Klein H, Kerstiens L, Koschmieder S, Skorski T. Genomic Instability Originates From Leukemia Stem Cells in a Mouse Model of CML-CP Blood. 118: 445-445. DOI: 10.1182/Blood.V118.21.445.445 |
0.836 |
|
| 2011 |
Nieborowska-Skorska M, Kopinski P, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Ambrozek M, Seferynska I, Niesiobedzka-Krezel J, Bolton E, ... ... Skorski T, et al. Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells Blood. 118: 2736-2736. DOI: 10.1182/Blood.V118.21.2736.2736 |
0.836 |
|
| 2010 |
Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. The Journal of Clinical Investigation. 120: 2254-64. PMID 20592475 DOI: 10.1172/Jci41246 |
0.456 |
|
| 2010 |
Dasgupta Y, Virgili A, Koptyra M, Nacheva EP, Skorski T. Sensitivity to Imatinib In BCR-ABL1-Positive Chronic Myeloid Leukemia Cells Depends on the Presence of Normal ABL1. Blood. 116: 3405-3405. DOI: 10.1182/Blood.V116.21.3405.3405 |
0.84 |
|
| 2010 |
Kopinski P, Nieborowska-Skorska M, Hoser G, Ngaba D, Ray R, Koptyra M, Bolton E, Seferynska I, Stoklosa T, Slupianek A, Reddy MR, Sattler M, Skorski T. Mitochondrial Respiratory Chain Complex III Causes Genomic Instability In CML-CP. Blood. 116: 1211-1211. DOI: 10.1182/Blood.V116.21.1211.1211 |
0.833 |
|
| 2010 |
Bolton E, Kamp L, Modi H, Bhatia R, Koschmieder S, Skorski T. CML-CP Mouse Model of Genomic Instability. Blood. 116: 1210-1210. DOI: 10.1182/Blood.V116.21.1210.1210 |
0.831 |
|
| 2010 |
Slupianek A, Dasgupta Y, Ren S, Cramer K, Skorski T. Targeting Phosphotyrosine-315 In RAD51 Recombinase to Prevent BCR-ABL1 - Mediated Unfaithful Homeologous Recombination Repair. Blood. 116: 1190-1190. DOI: 10.1182/Blood.V116.21.1190.1190 |
0.861 |
|
| 2009 |
Slupianek A, Jozwiakowski SK, Gurdek E, Skorski T. BCR/ABL kinase interacts with and phosphorylates the RAD51 paralog, RAD51B. Leukemia. 23: 2308-10. PMID 19657362 DOI: 10.1038/Leu.2009.164 |
0.415 |
|
| 2009 |
Slupianek A, Dasgupta Y, Ren S, Cramer K, Skorski T. Targeting BCR/ABL-RAD51 Interaction to Prevent Unfaithful Homeologous Recombination Repair. Blood. 114: 3272-3272. DOI: 10.1182/Blood.V114.22.3272.3272 |
0.851 |
|
| 2009 |
Nieborowska-Skorska M, Koptyra M, Bolton E, Ray R, Ngaba D, Hoser G, Stoklosa T, Slupianek A, Kopinski P, Skorski T. ROS-Induced DNA Damage Causing Genomic Instability in CML Stem and/or Progenitor Cells and in Quiescent and/or Proliferating Cells: Role of Mitochondrial Respiratory Chain Complex III. Blood. 114: 3268-3268. DOI: 10.1182/Blood.V114.22.3268.3268 |
0.833 |
|
| 2009 |
Stoklosa T, Koptyra M, Hoser G, Seferynska I, Glodkowska E, Skorski T. BCR/ABL Requires Fanconi Anemia D2 (FANCD2) Protein to Transform Hematopoetic Stem Cells. Blood. 114: 3249-3249. DOI: 10.1182/Blood.V114.22.3249.3249 |
0.657 |
|
| 2008 |
Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, Eaves CJ, Aulitzky W, Skorski T. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Research. 68: 6884-8. PMID 18757400 DOI: 10.1158/0008-5472.Can-08-1101 |
0.624 |
|
| 2008 |
Sliwinski T, Czechowska A, Szemraj J, Morawiec Z, Skorski T, Blasiak J. STI571 reduces NER activity in BCR/ABL-expressing cells. Mutation Research. 654: 162-7. PMID 18602021 DOI: 10.1016/J.Mrgentox.2008.06.002 |
0.588 |
|
| 2008 |
Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, Rayevskaya M, Seferynska I, Herrera L, Blasiak J, Skorski T. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Research. 68: 2576-80. PMID 18413724 DOI: 10.1158/0008-5472.Can-07-6858 |
0.543 |
|
| 2008 |
Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia. 22: 1969-72. PMID 18401418 DOI: 10.1038/Leu.2008.78 |
0.33 |
|
| 2008 |
Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leukemia & Lymphoma. 49: 610-4. PMID 18398719 DOI: 10.1080/03093640701859089 |
0.645 |
|
| 2008 |
Koptyra M, Stoklosa T, Hoser G, Seferynska I, Glodkowska E, Skorski T. Monoubiquitination of the Fanconi Anemia D2 (FANCD2) Protein Regulates the Transforming Potential of BCR/ABL Blood. 112: 3189-3189. DOI: 10.1182/Blood.V112.11.3189.3189 |
0.649 |
|
| 2008 |
Slupianek A, Ren S, Skorski T. Selective Anti-Leukemia Targeting of the Interaction Between BCR/ABL and Mammalian RecA Homologs Blood. 112: 195-195. DOI: 10.1182/Blood.V112.11.195.195 |
0.665 |
|
| 2008 |
Nieborowska-Skorska M, Koptyra M, Hoser G, Ray R, Ngaba D, Bolton E, Skorski T. Mechanisms Generating free Radicals in CML Stem/Progenitor Cell Populations Causing DNA Damage and Genomic Instability Blood. 112: 192-192. DOI: 10.1182/Blood.V112.11.192.192 |
0.837 |
|
| 2007 |
Skorski T. Genomic instability: The cause and effect of BCR/ABL tyrosine kinase. Current Hematologic Malignancy Reports. 2: 69-74. PMID 20425353 DOI: 10.1007/S11899-007-0010-6 |
0.635 |
|
| 2007 |
Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia. 21: 1347-52. PMID 17495971 DOI: 10.1038/Sj.Leu.2404733 |
0.306 |
|
| 2007 |
Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, Seferynska I, Reiss K, Skorski T. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood. 110: 651-60. PMID 17431132 DOI: 10.1182/Blood-2006-08-042630 |
0.828 |
|
| 2007 |
Cramer K, Penserga ET, Reddy A, Wosen J, Skorski T. BCR/ABL and Other Oncogenic Fusion Tyrosine Kinases (FTKs) Stimulate Single Strand Annealing (SSA), the Rare and Extremely Unfaithful DNA Double-Strand Break Repair Pathway To Facilitate Genomic Instability in Hematologic Malignancies. Blood. 110: 998-998. DOI: 10.1182/Blood.V110.11.998.998 |
0.597 |
|
| 2007 |
Nieborowska-Skorska M, Slupianek A, Stoklosa T, Poplawski T, Cramer K, Skorski T. BCR/ABL Kinase Elevates ROS-Mediated Oxidative DNA Damage in CML Stem/Progenitor Cells and Affects the Efficiency and Fidelity of DNA Repair To Induce Genetic Instability. Blood. 110: 34-34. DOI: 10.1182/Blood.V110.11.34.34 |
0.621 |
|
| 2007 |
Stoklosa T, Poplawski T, Basak G, Slupianek A, Blasiak J, Seferynska I, Skorski T. BCR/ABL Kinase Inhibits Mismatch Repair To Reduce Apoptosis and Induce Point Mutations. Blood. 110: 32-32. DOI: 10.1182/Blood.V110.11.32.32 |
0.63 |
|
| 2007 |
Slupianek A, Jozwiakowski S, Pytel D, Poplawski T, Nowicki M, Skorski T. BCR/ABL Stimulates WRN Helicase Activity To Facilitate DNA Double-Strand Breaks Repair. Blood. 110: 1024-1024. DOI: 10.1182/Blood.V110.11.1024.1024 |
0.618 |
|
| 2006 |
Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene. 26: 11-20. PMID 16785987 DOI: 10.1038/Sj.Onc.1209756 |
0.609 |
|
| 2006 |
Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, Koptyra M, Seferynska I, Krszyna K, Blasiak J, Skorski T. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle (Georgetown, Tex.). 5: 994-1000. PMID 16687921 DOI: 10.4161/Cc.5.9.2722 |
0.846 |
|
| 2006 |
Nieborowska-Skorska M, Hoser G, Rink L, Malecki M, Kossev P, Wasik MA, Skorski T. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Research. 66: 4108-16. PMID 16618731 DOI: 10.1158/0008-5472.Can-05-1584 |
0.778 |
|
| 2006 |
Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J, Skorski T. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 108: 319-27. PMID 16527898 DOI: 10.1182/Blood-2005-07-2815 |
0.501 |
|
| 2006 |
Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutation Research. 603: 74-82. PMID 16388976 DOI: 10.1182/Blood.V106.11.1525.1525 |
0.62 |
|
| 2006 |
Slupianek A, Nowicki MO, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. Dna Repair. 5: 243-50. PMID 16297667 DOI: 10.1016/J.Dnarep.2005.10.005 |
0.585 |
|
| 2006 |
Trojanek J, Croul S, Ho T, Wang JY, Darbinyan A, Nowicki M, Del Valle L, Skorski T, Khalili K, Reiss K. T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. Journal of Cellular Physiology. 206: 35-46. PMID 15965906 DOI: 10.1002/Jcp.20425 |
0.4 |
|
| 2006 |
Hartman AD, Wilson-Weekes A, Cripe LD, Bennett B, Friedman G, Worland P, Druker B, Ren S, Skorski T, Boswell HS. In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2. Blood. 108: 584-584. DOI: 10.1182/Blood.V108.11.584.584 |
0.489 |
|
| 2006 |
Bargaoanu M, Skorski T. Mutations in the BCR/ABL Kinase Encoding the Resistance to Imatinib Mesylate Do Not Modify the Sensitivity to Genotoxic Treatment. Blood. 108: 2194-2194. DOI: 10.1182/Blood.V108.11.2194.2194 |
0.56 |
|
| 2006 |
Rink L, Stoklosa T, Nieborowska-Skorska M, Slupianek A, Seferynska I, Skorski T. Enhanced Phosphorylation of Nbs1, a Member of DNA Repair/Checkpoint Complex RAD50-Mre11-Nbs1, Can Be Targeted Simultaneously with BCR/ABL Kinase To Eliminate Leukemia Cells. Blood. 108: 2127-2127. DOI: 10.1182/Blood.V108.11.2127.2127 |
0.854 |
|
| 2006 |
Koptyra M, Skorski T. Fanconi Anemia D2 (FANCD2) Is Required To Overcome Reactive Oxygen Species (ROS) - Induced DNA Double-Strand Breaks in BCR/ABL-Positive Leukemias. Blood. 108: 2119-2119. DOI: 10.1182/Blood.V108.11.2119.2119 |
0.623 |
|
| 2005 |
Ren SY, Xue F, Feng J, Skorski T. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Experimental Hematology. 33: 1222-8. PMID 16219545 DOI: 10.1016/J.Exphem.2005.06.030 |
0.513 |
|
| 2005 |
Ren SY, Bolton E, Mohi MG, Morrione A, Neel BG, Skorski T. Phosphatidylinositol 3-kinase p85α subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: Molecular mechanisms and biological consequences Molecular and Cellular Biology. 25: 8001-8008. PMID 16135792 DOI: 10.1128/Mcb.25.18.8001-8008.2005 |
0.798 |
|
| 2005 |
Wang JY, Ho T, Trojanek J, Chintapalli J, Grabacka M, Stoklosa T, Garcia FU, Skorski T, Reiss K. Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence. Oncogene. 24: 3748-58. PMID 15782124 DOI: 10.1038/Sj.Onc.1208537 |
0.512 |
|
| 2005 |
Slupianek A, Gurdek E, Koptyra M, Nowicki MO, Siddiqui KM, Groden J, Skorski T. BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin. Oncogene. 24: 3914-22. PMID 15750625 DOI: 10.1038/Sj.Onc.1208545 |
0.609 |
|
| 2005 |
Nieborowska M, Stoklosa T, Datta M, Czechowska A, Rink L, Blasiak J, Skorski T. ATR-Chk1 Axis Is Activated, but the Function of Chk1 Is Disrupted in BCR/ABL Leukemia Cells Responding to DNA Damage. Blood. 106: 2883-2883. DOI: 10.1182/Blood.V106.11.2883.2883 |
0.85 |
|
| 2005 |
Koptyra M, Houghtaling S, Grompe M, Skorski T. Fanconi Anemia D2 Protein Contributes to BCR/ABL-Mediated Transformation of Hematopoietic Cells. Blood. 106: 2878-2878. DOI: 10.1182/blood.V106.11.2878.2878 |
0.566 |
|
| 2005 |
Slupianek A, Jozwiakowski S, Gurdek E, Nowicki MO, Skorski T. BCR/ABL Regulates the Expression and Interacts with Werner Syndrome Helicase/Exonuclease To Modulate Its Biochemical Properties. Blood. 106: 2873-2873. DOI: 10.1182/Blood.V106.11.2873.2873 |
0.592 |
|
| 2005 |
Stoklosa T, Slupianek A, Basak G, Skorski T. BCR/ABL Kinase Disrupts Formation of Mismatch Repair Complex To Induce Genomic Instability. Blood. 106: 2864-2864. DOI: 10.1182/Blood.V106.11.2864.2864 |
0.575 |
|
| 2005 |
Slupianek A, Nowicki MO, Skorski T. BCR/ABL Modifies the Kinetics and Fidelity of DNA Double-Strand Breaks Repair in Leukemia Cells. Blood. 106: 1982-1982. DOI: 10.1182/Blood.V106.11.1982.1982 |
0.629 |
|
| 2004 |
Slupianek A, Skorski T. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Experimental Hematology. 32: 1265-71. PMID 15588951 DOI: 10.1016/J.Exphem.2004.11.002 |
0.472 |
|
| 2004 |
Stoklosa T, Slupianek A, Datta M, Nieborowska-Skorska M, Nowicki MO, Koptyra M, Skorski T. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle (Georgetown, Tex.). 3: 1463-72. PMID 15492510 DOI: 10.4161/Cc.3.11.1229 |
0.522 |
|
| 2004 |
Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 104: 3746-53. PMID 15304390 DOI: 10.1182/Blood-2004-05-1941 |
0.593 |
|
| 2004 |
Majsterek I, Slupianek A, Hoser G, Skórski T, Blasiak J. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance? Biochimie. 86: 53-65. PMID 14987801 DOI: 10.1016/J.Biochi.2003.10.008 |
0.548 |
|
| 2004 |
Chipitsyna G, Slonina D, Siddiqui K, Peruzzi F, Skorski T, Reiss K, Sawaya BE, Khalili K, Amini S. HIV-1 Tat increases cell survival in response to cisplatin by stimulating Rad51 gene expression. Oncogene. 23: 2664-71. PMID 14755242 DOI: 10.1038/Sj.Onc.1207417 |
0.553 |
|
| 2004 |
Koptyra M, Falinski R, Nowicki MO, Blasiak J, Skorski T. BCR/ABL Oncogenic Kinase Stimulates DNA Oxidative Damage To Induce Self-Mutagenesis Causing Resistance to Imatinib Mesylate. Blood. 104: 714-714. DOI: 10.1182/Blood.V104.11.714.714 |
0.56 |
|
| 2004 |
Ren S, Xue F, Feng J, Skorski T. Intrinsic Regulation of the Interactions between the SH3 Domain of p85 Subunit of Phosphatidylinositol-3 Kinase and BCR/ABL Oncogenic Tyrosine Kinase. Blood. 104: 2961-2961. DOI: 10.1182/Blood.V104.11.2961.2961 |
0.442 |
|
| 2004 |
Nieborowska-Skorska M, Hoser G, Malecki M, Wasik M, Skorski T. BCR/ABL→STAT5 Pathway Stimulates Helix-Loop-Helix Id-1 Protein To Enhance the MMP9 - Dependent Invasiveness of Leukemia Cells. Blood. 104: 2954-2954. DOI: 10.1182/Blood.V104.11.2954.2954 |
0.525 |
|
| 2004 |
Ren S, Bolton E, Skorski T. Phosphatidylinositol 3-Kinase p85 Subunit-Dependent Interaction with BCR/ABL: Molecular Mechanism and Biological Consequences. Blood. 104: 2953-2953. DOI: 10.1182/Blood.V104.11.2953.2953 |
0.797 |
|
| 2003 |
Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, Lassak A, Peruzzi F, Khalili K, Skorski T, Reiss K. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Molecular and Cellular Biology. 23: 7510-24. PMID 14559999 DOI: 10.1128/Mcb.23.21.7510-7524.2003 |
0.353 |
|
| 2003 |
Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS, Lautier D, Skorski T. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood. 102: 2632-7. PMID 12829601 DOI: 10.1182/Blood-2002-10-3207 |
0.556 |
|
| 2003 |
Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene. 22: 3952-63. PMID 12813469 DOI: 10.1038/Sj.Onc.1206620 |
0.441 |
|
| 2003 |
Blasiak J, Gloc E, Drzewoski J, Wozniak K, Zadrozny M, Skórski T, Pertynski T. Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells. Mutation Research. 535: 25-34. PMID 12547280 DOI: 10.1016/S1383-5718(02)00289-9 |
0.523 |
|
| 2003 |
Hoser G, Majsterek I, Romana DL, Slupianek A, Blasiak J, Skorski T. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? Leukemia Research. 27: 267-73. PMID 12537980 DOI: 10.1016/S0145-2126(02)00163-7 |
0.596 |
|
| 2002 |
Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene. 21: 8591-604. PMID 12476306 DOI: 10.1038/Sj.Onc.1206087 |
0.425 |
|
| 2002 |
Błasiak J, Gloc E, Młynarski W, Drzewoski J, Skórski T. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leukemia Research. 26: 1093-6. PMID 12443881 DOI: 10.1016/S0145-2126(02)00051-6 |
0.565 |
|
| 2002 |
Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. The Embo Journal. 21: 5766-74. PMID 12411494 DOI: 10.1093/Emboj/Cdf562 |
0.502 |
|
| 2002 |
Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 21: 5868-76. PMID 12185586 DOI: 10.1038/Sj.Onc.1205724 |
0.546 |
|
| 2002 |
Gloc E, Warszawski M, Młynarski W, Stolarska M, Hoser G, Skorski T, Błasiak J. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine. Acta Biochimica Polonica. 49: 121-8. PMID 12136932 |
0.423 |
|
| 2002 |
Błasiak J, Gloc E, Woźniak K, Młynarski W, Stolarska M, Skórski T, Majsterek I. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chemico-Biological Interactions. 140: 1-18. PMID 12044557 DOI: 10.1016/S0009-2797(02)00012-1 |
0.472 |
|
| 2002 |
Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nature Reviews. Cancer. 2: 351-60. PMID 12044011 DOI: 10.1038/Nrc799 |
0.522 |
|
| 2002 |
Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood. 99: 4531-9. PMID 12036885 DOI: 10.1182/Blood.V99.12.4531 |
0.451 |
|
| 2002 |
Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Molecular and Cellular Biology. 22: 4189-201. PMID 12024032 DOI: 10.1128/Mcb.22.12.4189-4201.2002 |
0.508 |
|
| 2002 |
Majsterek I, Blasiak J, Mlynarski W, Hoser G, Skórski T. Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells? Cell Biology International. 26: 363-70. PMID 11991666 DOI: 10.1006/Cbir.2002.0865 |
0.58 |
|
| 2002 |
Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. Journal of Immunology (Baltimore, Md. : 1950). 168: 466-74. PMID 11751994 DOI: 10.4049/Jimmunol.168.1.466 |
0.529 |
|
| 2001 |
Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance Molecular Cell. 8: 795-806. PMID 11684015 DOI: 10.1016/S1097-2765(01)00357-4 |
0.578 |
|
| 2001 |
Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel R, Greene MI. Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1 Oncogene. 20: 4640-4649. PMID 11498787 DOI: 10.1038/Sj.Onc.1204625 |
0.336 |
|
| 2000 |
Nieborowska-Skorska M, Slupianek A, Skorski T. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells. Oncogene. 19: 4117-24. PMID 10962572 DOI: 10.1038/Sj.Onc.1203754 |
0.474 |
|
| 1999 |
Putney SD, Brown J, Cucco C, Lee R, Skorski T, Leonetti C, Geiser T, Calabretta B, Zupi G, Zon G. Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense & Nucleic Acid Drug Development. 9: 451-8. PMID 10555152 DOI: 10.1089/Oli.1.1999.9.451 |
0.311 |
|
| 1999 |
Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. The Journal of Experimental Medicine. 189: 1229-42. PMID 10209040 DOI: 10.1084/Jem.189.8.1229 |
0.501 |
|
| 1999 |
Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, Eichstetter I. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 96: 3092-7. PMID 10077642 DOI: 10.1073/Pnas.96.6.3092 |
0.401 |
|
| 1998 |
Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, Majewski M, Wasik M, Calabretta B. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac Proceedings of the National Academy of Sciences of the United States of America. 95: 11858-11862. PMID 9751755 DOI: 10.1073/Pnas.95.20.11858 |
0.537 |
|
| 1998 |
Perrotti D, Bonatti S, Trotta R, Martinez R, Skorski T, Salomoni P, Grassilli E, Lozzo RV, Cooper DR, Calabretta B. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. The Embo Journal. 17: 4442-55. PMID 9687511 DOI: 10.1093/Emboj/17.15.4442 |
0.505 |
|
| 1998 |
Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, Calabretta B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. The Journal of Experimental Medicine. 187: 1995-2007. PMID 9625759 DOI: 10.1084/Jem.187.12.1995 |
0.412 |
|
| 1998 |
Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P, Antonyak M, Martinez R, Majewski M, Wong A, Perussia B, Calabretta B. The SH3 Domain Contributes to BCR/ABL-Dependent Leukemogenesis In Vivo: Role in Adhesion, Invasion, and Homing Blood. 91: 406-418. DOI: 10.1182/Blood.V91.2.406.406_406_418 |
0.504 |
|
| 1997 |
Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway Embo Journal. 16: 6151-6161. PMID 9321394 DOI: 10.1093/Emboj/16.20.6151 |
0.399 |
|
| 1997 |
Calabretta B, Skorski T. Gene regulatory mechanisms operative on hematopoietic cells: proliferation, differentiation, and neoplasia. Critical Reviews in Eukaryotic Gene Expression. 7: 117-24. PMID 9034718 DOI: 10.1615/Critreveukargeneexpr.V7.I1-2.70 |
0.418 |
|
| 1997 |
Calabretta B, Skorski T. BCR/ABL regulation of PI-3 kinase activity. Leukemia & Lymphoma. 23: 473-6. PMID 9031078 DOI: 10.3109/10428199609054856 |
0.423 |
|
| 1997 |
Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. Journal of the National Cancer Institute. 89: 124-33. PMID 8998181 DOI: 10.1093/Jnci/89.2.124 |
0.371 |
|
| 1997 |
Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, Iozzo RV. Ectopic expression of decorin protein core causes generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases Matrix Biology. 16: 121. DOI: 10.1016/S0945-053X(97)90047-0 |
0.382 |
|
| 1996 |
Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA, Calabretta B. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 93: 13137-42. PMID 8917557 DOI: 10.1073/Pnas.93.23.13137 |
0.351 |
|
| 1996 |
Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. The Journal of Experimental Medicine. 182: 1645-53. PMID 7500009 DOI: 10.1084/Jem.182.6.1645 |
0.342 |
|
| 1996 |
Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo R, Calabretta B. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice Blood. 88: 1005-1012. DOI: 10.1182/Blood.V88.3.1005.1005 |
0.352 |
|
| 1995 |
Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 92: 7016-20. PMID 7624361 DOI: 10.1073/Pnas.92.15.7016 |
0.408 |
|
| 1995 |
Perrotti D, Melotti P, Skorski T, Casella I, Peschle C, Calabretta B. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Molecular and Cellular Biology. 15: 6075-87. PMID 7565760 DOI: 10.1128/Mcb.15.11.6075 |
0.315 |
|
| 1995 |
Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M, Wen S, Zon G, Gewirtz A, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells Blood. 86: 726-736. DOI: 10.1182/Blood.V86.2.726.Bloodjournal862726 |
0.433 |
|
| 1994 |
Skorski T, Kanakaraj P, Ku DH, Nieborowska-Skorska M, Canaani E, Zon G, Perussia B, Calabretta B. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. The Journal of Experimental Medicine. 179: 1855-65. PMID 8195713 DOI: 10.1084/Jem.179.6.1855 |
0.463 |
|
| 1994 |
Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proceedings of the National Academy of Sciences of the United States of America. 91: 4504-8. PMID 8183938 DOI: 10.1073/Pnas.91.10.4504 |
0.314 |
|
| 1993 |
Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szcyzlik C, Chen ST, Lange B, Calabretta B. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. The Journal of Clinical Investigation. 92: 194-202. PMID 8325984 DOI: 10.1172/Jci116549 |
0.387 |
|
| 1993 |
Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M, Szczylik C, Zon G, Arlinghaus RB, Gewirtz A, Perussia B, Calabretta B. p120 GAP requirement in normal and malignant human hematopoiesis Journal of Experimental Medicine. 178: 1923-1933. PMID 8245773 DOI: 10.1084/Jem.178.6.1923 |
0.393 |
|
| 1991 |
Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science (New York, N.Y.). 253: 562-5. PMID 1857987 DOI: 10.1126/Science.1857987 |
0.409 |
|
| Show low-probability matches. |